Market, Publisher's note

Institutional research is flawed. I’m teaming with Endpoints to help democratize it

As someone who consumes a lot of research, it has become increasingly clear to me that this is an industry reaching only a fraction of its full potential. The research market is ripe for disruption.

Consider the following:

  • Sell-side research (Wall Street research) is not always independent and can be influenced by banking relationships a firm has with the companies it covers.
  • Most research is only available to investor clients of the specific bank. Many potential consumers are being shut out. Companies with no banking needs, foundations, and other institutions want access to first-rate research as well. Those who don’t trade stocks and generate resulting fees need not be left out.
  • There are many independent KOL’s who bring unique expertise to a specific research topic that would be valuable if shared widely. However, most do not have the distribution network available to make it possible.
  • The research business is going through important fundamental change. A new law implemented in Europe requires that clients pay for research directly rather than through trading fees. This means that the consumption of research and the value placed on it in the future will be more closely aligned with the quality of content (as it should be). It also means that by taking the trading desk relationship out of the equation, the brand name of the institution behind it matters much less…if at all. Content is king.

All of this can be done a better way. That is why I wanted to team up with an independent media organization like Endpoints News to create a platform that can democratize and change the research business. Endpoints is a first-class publisher with a unique focus on biotech who shares this vision of changing research for the better.

Visit Endpoints Exchange

Together via Endpoints Exchange, we will make it possible for anyone with unique expertise to create excellent research for institutional consumption and get it in the hands of all who are willing to pay. For consumers out there, all are welcome here…no banking relationship required. We are removing the inefficiencies and biases of the current system out of the equation and democratizing it on both sides. This will be research by the biotech community for the biotech community.

If you are an expert in a particular field, please reach out to us if you would like to share your insights with the biotech world. We want to help maximize your exposure and impact. However, Endpoints Exchange will have a rigorous evaluation process and acceptance policy. We currently plan to make available only one report at a time because our goal is to showcase only the best of the best. This illustrates our quality commitment to consumers and will also benefit publishers who make the cut by giving them the strongest spotlight possible.

And if you are one of those underserved consumers, we hope you enjoy what our experts have to share. Having the highest standards and a rigorous quality filtering process is a top priority. We will be very thoughtful about what reports find a home here so you can be confident that this will be a place of excellence. Our commitment to you is that any report that makes Endpoints Exchange will be worthy your valuable attention.

We hope you enjoy Endpoints Exchange and that it will become a valuable new asset for the biotech community. Please always let us know how we can improve this platform over time to better fit your needs.

Brad Loncar is an independent biotechnology investor and analyst. He can be reached on Twitter at @bradloncar.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->